How comparing works here
How do I compare two companies?
Type the tickers into the box above — up to five at once. Every row is read from the companies' own annual filings, so a comparison shows the same measure computed the same way for each of them rather than whatever each company chose to highlight.
Can I compare an ETF with a stock?
Yes, and the table changes to suit. Two funds are compared on cost, income, spread and record, because revenue growth and debt mean nothing for a fund. A fund against a company shows only what both of them have.
Side by side
Compare
Put up to 4 companies, funds, commodities or coins next to each other — health, valuation, growth and performance.
Every row is computed the same way for every column, from each company's own annual filing, so a comparison is not a collection of whichever figures each of them chose to put in a press release. Funds are compared on what a fund is actually judged on: cost, income, spread and record.
Relative performance
Rebased so every symbol starts at 0%
Loading price history…
Side by side
Latest annual figures from each company's filings
| Metric | ZBHZIMMER BIOMET HOLDINGS, INC. | EWEdwards Lifesciences Corp | IDXXIDEXX LABORATORIES INC /DE | RMDRESMED INC | Median of the restexcluding ZBH |
|---|---|---|---|---|---|
| Type | Company | Company | Company | Company | |
| Price | $98.81▲ 3.95 (4.16%) | $90.09▲ 1.69 (1.91%) | $566.76▲ 13.28 (2.40%) | $253.06▲ 6.86 (2.79%) | |
| Health scoreComposite of profitability, growth, debt and accounting quality. | 7.0/10 | 9.0/10 | 9.0/10 | 9.0/10 | 9.0/10 |
| Market value | $19.67B | $52.32B | $45.18B | $36.50B | |
| Revenue | $8.23B | $6.07B | $4.30B | $5.65B | |
| Profit | $705.1M | $1.07B | $1.06B | $1.52B | |
| Revenue growthChange in sales versus the prior year. | 7.2% | 11.5% | 10.4% | 9.9% | 10.4% |
| Gross marginShare of sales left after the direct cost of producing them. | 69.7% | 78.0% | 61.8% | 61.1% | 61.8% |
| Operating marginShare of sales left after running the business, before interest and tax. | 13.3% | 20.8% | 31.6% | 33.4% | 31.6% |
| Profit marginProfit kept from each dollar of sales. | 8.6% | 17.7% | 24.6% | 26.9% | 24.6% |
| Free cash flow marginCash left after capital spending, as a share of sales. | 17.9% | 22.0% | 24.6% | 29.2% | 24.6% |
| Return on equityProfit against the owners' stake in the company. | 5.6% | 10.4% | 66.0% | 23.1% | 23.1% |
| Return on invested capital (approx.)Operating profit after tax against equity plus debt, less cash. Cash here excludes short-term investments, so this runs low for cash-rich companies. | 4.7% | 13.3% | 58.0% | 25.9% | 25.9% |
| P/E ratioPrice paid per dollar of annual profit. | 27.90x | 48.73x | 42.64x | 23.96x | 42.64x |
| EV / EBITDA (approx.)Market value plus debt less cash, against operating profit before depreciation. Cash excludes short-term investments, so this runs high for cash-rich companies. | 12.13x | 35.17x | 30.19x | 17.09x | 30.19x |
| Price to book | 1.55x | 5.06x | 28.14x | 5.54x | 5.54x |
| Debt to equityTotal liabilities compared with owners' stake. | 0.82x | 0.32x | 1.09x | 0.36x | 0.36x |
| Piotroski F-ScoreNine checks of financial strength. Higher is stronger. | 5/9 | 6/9 | 8/9 | 8/9 | 8.0 |
| Bankruptcy riskAltman Z-Score zone. | grey | safe | safe | safe |
How ZBH compares with the others
- ZBH's operating margin of 13.3% is lower than the median of the other companies selected (31.6%).
- Its revenue grew more slowly than the median of the other companies selected: 7.2% against 10.4%.
- It trades at a lower P/E than the median of the other companies selected: 27.9x against 42.6x.
- Its liabilities are higher relative to equity than the median of the other companies selected: 0.8x against 0.4x.
Measured against the other companies entered, from each one's latest annual filing. A difference describes the companies; it does not rank them.